You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The financing will be used to advance the firm's drug discovery platform, which combines high-throughput wet lab experimentation with artificial intelligence.
UgenTec will develop artificially intelligent software to support interpretation of MDxHealth's ConfirMDx and SelectMDx molecular prostate cancer tests.
Rhythm is using WuXi's artificial intelligence capabilities to support drug development targeting pathways associated with genetic obesity syndromes.
Three-month-old health data integrator Datavant hopes its analytics technology can improve the speed and success of clinical trials.
The companies are planning to develop individual disease diagnostics, and then a universal diagnostic from a single blood test.
The companies plan to combine their expertise in artificial intelligence and genomic data analyses to develop new precision medicine tools.
The Boston-based hospitals will provide Berg access to clinically annotated patient-derived specimens to track neurological disease pathology and develop diagnostic tools.
PreventionGenetics will use FDNA's technology to expand the diagnostic ability of its testing and interpretation services.
Envisagenics, which was spun out of Cold Spring Harbor Laboratory, has developed a platform to help drug companies address RNA splicing errors.
The Universal Influenza Vaccine Initiative, led by Vanderbilt and the Human Vaccines Project, has turned to omics and AI to create more effective flu vaccines.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.